8-KEarnings & Results

DEXCOM INC 8-K Report, Financial Results (Jan 12, 2016)

Filed January 12, 2016For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on January 12, 2016, providing preliminary financial results and a future outlook. The company reported robust sequential and year-over-year revenue growth for the fourth quarter of 2015, with estimated revenues of approximately $129 million. For the full fiscal year 2015, DexCom's estimated revenue reached approximately $400 million, representing significant growth of about 54% compared to 2014. This performance indicates strong market adoption and execution by the company. Additionally, the company disclosed a growing global patient base, estimated to be between 140,000 and 150,000 by the end of 2015, with international patients comprising 20-25% of this base. The outlook for fiscal year 2016 is also positive, with projected revenues between $540 million and $565 million. DexCom anticipates maintaining a healthy gross margin of 67% to 70%. While expecting a roughly 25% increase in cash-based operating expenses, the company plans to invest an additional $40 million in strategic initiatives. These investments are earmarked for key areas such as their partnership with Verily, the development of their data platform, and expansion of manufacturing capacity and commercial operations. DexCom also expects continued increases in cash-based net income over 2015 levels, suggesting a focus on profitability alongside growth.

Key Highlights

  • 1Q4 2015 estimated revenue of approximately $129 million, a 23% sequential increase and a 53% year-over-year increase.
  • 2Fiscal year 2015 estimated revenue of approximately $400 million, representing 54% growth over fiscal year 2014.
  • 3Global patient base estimated between 140,000 and 150,000 as of December 31, 2015.
  • 420% to 25% of the global patient base resides outside the United States.
  • 5Fiscal year 2016 revenue guidance projected to be between $540 million and $565 million.
  • 6Fiscal year 2016 gross margin guidance expected to be in the range of 67% to 70%.
  • 7Planned investment of approximately $40 million in strategic initiatives for FY2016, including Verily partnership, data platform, and expansion.

Frequently Asked Questions

For the fourth quarter of 2015, DexCom estimated revenues of approximately $129 million, up about 23% sequentially and 53% year-over-year. For the full fiscal year 2015, estimated revenues were approximately $400 million, a 54% increase from 2014.

DexCom projects fiscal year 2016 revenues to be in the range of $540 million to $565 million. The company also anticipates a gross margin of 67% to 70% and expects continued increases in cash-based net income compared to 2015.

DexCom plans to invest approximately $40 million in additional cash-based expenditures for strategic initiatives. These include their partnership with Verily, development of their data platform, and expansion of manufacturing capacity and commercial operations.

As of December 31, 2015, DexCom's estimated global patient base was between 140,000 and 150,000. Approximately 20% to 25% of these patients were located outside the United States, indicating a growing international market presence.